Literature DB >> 18765095

Angiotensin-(1-7) as an antihypertensive, antifibrotic target.

Michael J Katovich1, Justin L Grobe, Mohan K Raizada.   

Abstract

Over the past two decades, enormous progress has been made in understanding the possible physiological significance of alternate renin-angiotensin system processing pathways and angiotensin fragments, such as angiotensin (Ang)-(1-7). Evidence from in vivo and ex vivo studies in humans and various animal models suggests a possible role for this heptapeptide in blood pressure regulation, although the mechanisms involved are most likely indirect, involving some combination of bradykinin and nitric oxide signaling. In contrast, a growing body of in vivo and in vitro evidence supports direct cardioprotective (antihypertrophic, antifibrotic) actions of Ang-(1-7). Here, we review key studies investigating the blood pressure and tissue-protective roles of Ang-(1-7), and summarize potential genomic and pharmacologic therapeutic strategies previously advanced by our group and others.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765095     DOI: 10.1007/s11906-008-0043-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  49 in total

1.  Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats.

Authors:  C V Lima; R D Paula; F L Resende; M C Khosla; R A Santos
Journal:  Hypertension       Date:  1997-09       Impact factor: 10.190

2.  Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects.

Authors:  Michikado Iwata; Randy T Cowling; Devorah Gurantz; Cristina Moore; Shen Zhang; Jason X-J Yuan; Barry H Greenberg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-15       Impact factor: 4.733

3.  Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats.

Authors:  Matthew J Huentelman; Justin L Grobe; Jorge Vazquez; Jillian M Stewart; Adam P Mecca; Michael J Katovich; Carlos M Ferrario; Mohan K Raizada
Journal:  Exp Physiol       Date:  2005-07-27       Impact factor: 2.969

4.  Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats.

Authors:  Pia E Walters; Tracey A Gaspari; Robert E Widdop
Journal:  Hypertension       Date:  2005-03-14       Impact factor: 10.190

5.  Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats.

Authors:  Annemarieke E Loot; Anton J M Roks; Robert H Henning; René A Tio; Albert J H Suurmeijer; Frans Boomsma; Wiek H van Gilst
Journal:  Circulation       Date:  2002-04-02       Impact factor: 29.690

6.  Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor.

Authors:  Matthew J Huentelman; Jasenka Zubcevic; Jose A Hernández Prada; Xiaodong Xiao; Dimiter S Dimitrov; Mohan K Raizada; David A Ostrov
Journal:  Hypertension       Date:  2004-10-18       Impact factor: 10.190

7.  Evidence that prolyl endopeptidase participates in the processing of brain angiotensin.

Authors:  W R Welches; R A Santos; M C Chappell; K B Brosnihan; L J Greene; C M Ferrario
Journal:  J Hypertens       Date:  1991-07       Impact factor: 4.844

8.  Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors.

Authors:  R A Santos; M J Campagnole-Santos; N C Baracho; M A Fontes; L C Silva; L A Neves; D R Oliveira; S M Caligiorne; A R Rodrigues; C Gropen Júnior
Journal:  Brain Res Bull       Date:  1994       Impact factor: 4.077

9.  Converting enzyme determines plasma clearance of angiotensin-(1-7).

Authors:  K Yamada; S N Iyer; M C Chappell; D Ganten; C M Ferrario
Journal:  Hypertension       Date:  1998-09       Impact factor: 10.190

Review 10.  Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.

Authors:  K T Weber; C G Brilla
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

View more
  17 in total

1.  Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment.

Authors:  Tammy C Lee; Dana Greene-Schloesser; Valerie Payne; Debra I Diz; Fang-Chi Hsu; Mitra Kooshki; Rashida Mustafa; David R Riddle; Weiling Zhao; Michael D Chan; Mike E Robbins
Journal:  Radiat Res       Date:  2012-06-12       Impact factor: 2.841

2.  Reduction of angiotensin A and alamandine vasoactivity in the rabbit model of atherogenesis: differential effects of alamandine and Ang(1-7).

Authors:  Belthrand Habiyakare; Hiba Alsaadon; Michael L Mathai; Alan Hayes; Anthony Zulli
Journal:  Int J Exp Pathol       Date:  2014-06-20       Impact factor: 1.925

3.  Angiotensin-(1-7) reverses angiogenic dysfunction in corpus cavernosum by acting on the microvasculature and bone marrow-derived cells in diabetes.

Authors:  Neha Singh; Goutham Vasam; Rahul Pawar; Yagna P R Jarajapu
Journal:  J Sex Med       Date:  2014-06-23       Impact factor: 3.802

Review 4.  The renin-angiotensin system and prevention of age-related functional decline: where are we now?

Authors:  Corey B Simon; Brittany Lee-McMullen; Dane Phelan; Janine Gilkes; Christy S Carter; Thomas W Buford
Journal:  Age (Dordr)       Date:  2015-02-09

5.  Chronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy.

Authors:  Rasna Sabharwal; Michael Z Cicha; Ruben D M Sinisterra; Frederico B De Sousa; Robson A Santos; Mark W Chapleau
Journal:  Clin Sci (Lond)       Date:  2014-07       Impact factor: 6.124

6.  Beneficial Effects of Angiotensin-(1-7) on CD34+ Cells From Patients With Heart Failure.

Authors:  Colleen T Cole-Jeffrey; Carl J Pepine; Michael J Katovich; Maria B Grant; Mohan K Raizada; Sugata Hazra
Journal:  J Cardiovasc Pharmacol       Date:  2018-03       Impact factor: 3.105

7.  Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure.

Authors:  Wen-na Zong; Xiao-hui Yang; Xiu-mei Chen; Hong-juan Huang; Hong-jian Zheng; Xiao-yi Qin; Yong-hong Yong; Kejiang Cao; Jun Huang; Xin-zheng Lu
Journal:  Acta Pharmacol Sin       Date:  2011-10-03       Impact factor: 6.150

8.  The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.

Authors:  Vinayak Shenoy; Anderson J Ferreira; Yanfei Qi; Rodrigo A Fraga-Silva; Carlos Díez-Freire; Autumn Dooies; Joo Yun Jun; Srinivas Sriramula; Nithya Mariappan; Dorna Pourang; Changaram S Venugopal; Joseph Francis; Timothy Reudelhuber; Robson A Santos; Jawaharlal M Patel; Mohan K Raizada; Michael J Katovich
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

9.  Angiotensin-(1-7) recruits muscle microvasculature and enhances insulin's metabolic action via mas receptor.

Authors:  Zhuo Fu; Lina Zhao; Kevin W Aylor; Robert M Carey; Eugene J Barrett; Zhenqi Liu
Journal:  Hypertension       Date:  2014-04-07       Impact factor: 10.190

10.  Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes?

Authors:  Ranjit Singh Padda; Yixuan Shi; Chao-Sheng Lo; Shao-Ling Zhang; John S D Chan
Journal:  J Diabetes Metab       Date:  2015-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.